Panacea Biotec Limited has submitted a regulatory disclosure to the National Stock Exchange of India Limited and BSE Limited regarding an upcoming board meeting.
The disclosure, made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announces that:
- The Board of Directors meeting is scheduled for Thursday, August 13, 2026, to be held in New Delhi
- The primary agenda is to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30, 2026 (Q1 FY27)
- Notice of the meeting will be uploaded on the company's website as required under Regulation 46(2) of SEBI LODR Regulations
- The trading window closure for all Designated Persons (including their Immediate Relatives) remains in effect from July 01, 2026 until August 15, 2026, as previously announced on June 26, 2026
- The trading window closure is implemented under the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015
The document was digitally signed by Ankit Jain, General Manager - Legal & Company Secretary, on August 08, 2026, at 14:27:28 IST.